
This Week in Dermatology — Jul 3, 2026
Notas del episodio
Editor's Pick: Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials (The British journal of dermatology, 2026)
Welcome to This Week in Dermatology. This week we are covering seven notable papers spanning novel oral therapeutics for psoriasis, hair loss interventions, and complex dermatopathological entities. Let's dive in. We begin with a major development in the management of moderate-to-severe plaque psoriasis.
This week's papers:
- Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.. The British journal of dermatology 2026
- Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study.. Journal of the American Academy of Dermatology 2026
- Safety of Biologic Therapy in Psoriasis Patients With Malignancy.. Journal of the American Academy of Dermatology 2026
- Comparative Alopecia Outcomes After Copper and Hormonal Intrauterine Device Placement: A TriNetX Database Retrospective Cohort Study.. Journal of the American Academy of Dermatology 2026
- Microneedling with adipose MSC exosomes versus monotherapy for androgenetic alopecia.. Journal of the European Academy of Dermatology and Venereology : JEADV 2026
- Clinicopathological features of lymphocytic thrombophilic arteritis and the relationship with livedoid vasculopathy - a case series of 36 patients.. The British journal of dermatology 2026
- Genomic Predictors of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Insights from an MD Anderson Cohort.. Journal of the American Academy of Dermatology 2026
Todos los episodios de AudioScholar Dermatology Weekly (India)